Consensus Guideline for the Diagnosis and Treatment of Tyrosine Hydroxylase (TH) Deficiency
Por:
Bondarenko, MS, Kuseyri Hübschmann, O, Kulhánek, J, Pons, R, Pearson, TS, Jeltsch, K, Badnjarevic, I, Wassenberg, T, Horvath, G, Stevanovic, G, Kurian, MA, Cortès-Saladelafont, E, Roubertie, A, Leuzzi, V, Bertoldi, M, Mastrangelo, M, Assmann, B, Garcia-Cazorla, A and Opladen, T
Publicada:
10 nov 2025
Resumen:
Tyrosine hydroxylase (TH) catalyses the rate-limiting step in dopamine biosynthesis. Autosomal recessive tyrosine hydroxylase deficiency (THD) leads to clinical phenotypes reflecting the deficiency of dopamine, norepinephrine, or epinephrine in the central nervous system (CNS), presenting along a continuous spectrum from mild to severe forms of the disease. The diagnosis is suggested by the detection of low CSF homovanillic acid (HVA) and confirmed by identifying biallelic pathogenic variants in the TH gene. L-dopa/decarboxylase inhibitor (DCI) supplementation is often the first-line treatment, and most patients have a good therapeutic response. However, initiation of therapy can be challenging in patients with severe disease forms who develop L-dopa/DCI-induced dyskinesia. Therefore, alternative treatment options, such as monoamine oxidase (MAO) inhibitors, must be evaluated to optimize motor symptom control. Clinical experience suggests that early diagnosis and treatment initiation may improve the outcome. Additionally, a multidisciplinary treatment approach should be utilized to monitor neurocognitive development and other comorbidities that may occur in THD. In this consensus guideline, representatives of the International Working Group on Neurotransmitter related Disorders (iNTD) and patient advocates evaluated all the evidence available in the literature on the diagnosis and management of THD and developed recommendations using the SIGN and GRADE methodologies. Based on the limited evidence, practical recommendations have been developed to support clinical diagnosis, laboratory testing, neuroimaging, medical treatment, and non-medical interventions. Research topics for further development were identified. This guideline aims to improve the care of patients with THD worldwide and raise general awareness of this rare disease.
Filiaciones:
Bondarenko, MS:
Hosp St Joan de Deu, Inst Pediat Recerca, Neurol Dept, Neurometab Unit, Barcelona, Spain
Hosp St Joan de Deu, Inst Pediat Recerca, Neurol Dept, Synapt Metab Lab, Barcelona, Spain
Hosp Universitari Germans Trias I Pujol, Pediat Dept, Neuropediat Unit, Badalona, Spain
Kuseyri Hübschmann, O:
Heidelberg Univ, Ctr Pediat & Adolescent Med, Med Fac Heidelberg, Div Pediat Neurol & Metab Med,Dept 1, Heidelberg, Germany
Kulhánek, J:
Charles Univ Prague, Dept Pediat & Inherited Metab Disorders, Prague, Czech Republic
Gen Univ Hosp Prague, Prague, Czech Republic
Pons, R:
Natl & Kapodistrian Univ Athens, Agia Sofia Hosp, Dept Pediat 1, Athens, Greece
Pearson, TS:
Ohio State Univ, Nationwide Childrens Hosp, Coll Med, Div Neurol, Columbus, OH USA
Jeltsch, K:
Heidelberg Univ, Ctr Pediat & Adolescent Med, Med Fac Heidelberg, Div Pediat Neurol & Metab Med,Dept 1, Heidelberg, Germany
Badnjarevic, I:
Lil Brave One Hrabrisa Patient Org Rare Neurotrans, Novi Sad, Serbia
Wassenberg, T:
Univ Ziekenhuis Brussel, Dept Pediat, Pediat Neurol & Metab Unit, Res Grp Vital, Brussels, Belgium
Horvath, G:
Vancouver Gen Hosp, Div Biochem Genet, Vancouver, BC, Canada
BC Childrens Hosp, Vancouver, BC, Canada
Stevanovic, G:
Clin Neurol & Psychiat Children & Youth, Belgrade, Serbia
Kurian, MA:
UCL GOS ICH, Zayed Ctr Res, Dev Neurosci, London, England
Great Ormond St Hosp Sick Children, Dept Neurol, London, England
Roubertie, A:
CHU Montpellier, Neuropediat Serv, Montpellier, France
Leuzzi, V:
Sapienza Univ, Dept Human Neurosci Child Neurol & Psychiat, Rome, Italy
Bertoldi, M:
Verona Univ, Dept Neurosci Biomed & Movement Sci, Verona, Italy
Mastrangelo, M:
Policlin Umberto 1, Dept Neurosci Mental Hlth, Child Neurol & Psychiat Unit, Rome, Italy
Assmann, B:
Heidelberg Univ, Ctr Pediat & Adolescent Med, Med Fac Heidelberg, Div Pediat Neurol & Metab Med,Dept 1, Heidelberg, Germany
Garcia-Cazorla, A:
Hosp St Joan de Deu, Inst Pediat Recerca, Neurol Dept, Neurometab Unit, Barcelona, Spain
Hosp St Joan de Deu, Inst Pediat Recerca, Neurol Dept, Synapt Metab Lab, Barcelona, Spain
Opladen, T:
Heidelberg Univ, Ctr Pediat & Adolescent Med, Med Fac Heidelberg, Div Pediat Neurol & Metab Med,Dept 1, Heidelberg, Germany
Son Llatzer Univ Hosp, Pediat Dept, Palma De Mallorca, Mallorca, Spain
Green Submitted, hybrid
|